FivePrime is discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant proteins in the human body to find the best protein for treatment of a given clinical indication. FivePrime’s ProScreen Engine enables the rapid production and screening of all therapeutically relevant proteins in medically-focused assays at the highest quality standards in the industry. This powerful approach is the polar opposite of the industry’s traditional “one protein at a time”. The ProScreen Engine comprises the definitive protein collection and screening process for biologics discovery and is unprecedented in its efficiency, quality and scale. In addition to DBL Investors, investors include Domain Associates, Versant Ventures, Kleiner Perkins Caufield and Byers, Texas Pacific Group, HealthCap and Advanced Technology Ventures.